Table 1: The relationship between mean
value of N/L, P/L ratio, CRP and clinical characteristics in stable
COPD.
|
# of
patients |
NLR |
PLR |
|||
|
|
|
median
(IQR) |
p-value |
median
(IQR) |
p-value |
|
History
of smoking |
|
|
|
||
|
quited smoking |
23
(58.9) |
2.06
(1.44-2.82) |
0.669 |
132.09
(87.44-185.06) |
0.392 |
|
still smoking |
16
(41.1) |
2.19
(1.51-3.04) |
|
154.51
(100.30-189.33) |
|
|
CV
comorbidities |
|
|
|
||
|
+ |
17
(43.6) |
2.50
(1.41-3.68) |
0.539 |
157.50
(89.99-187.83) |
0.605 |
|
- |
22
(56.4) |
1.90
(1.52-2.84) |
|
131.47
(98.58-209.21) |
|
|
GOLD
stage |
|
|
|
||
|
A+B |
14
(35.9) |
1.74
(1.42-2.35) |
0.091 |
98.86
(80.00-156.50) |
0.011 |
|
C+D |
25
(63.1) |
2.55
(1.64-3.15) |
|
157.55(118.67-
206.16) |
|
|
Exacerbetions |
|
|
|
||
|
<
2/year |
31
(79.5) |
2.03
(1.44-2.92) |
0.332 |
131.47
(90.59-178.95) |
0.176 |
|
≥
2/year |
8
(20.5) |
2.55
(1.85-3.78) |
|
184.94
(110.76-213.58) |
|
|
Severity
of dyspnea |
|
|
|
||
|
mMRC < 2 |
10
(25.6) |
1.65(1.30-2.39) |
0.497 |
115.60
(87.44-157.55) |
0.100 |
|
mMRC ≥ 2 |
29
(74.4) |
2.43
(1.60-3.15) |
|
151.52
(100.49-201.16) |
|
|
FEV1 |
|
|
|
||
|
<
50% |
26
(66.7) |
2.55
(1.64-3.15) |
0.091 |
157.55
(118.67-206.16) |
0.011 |
|
≥ 50% |
13
(33.3) |
1.74
(1.42-2.35) |
|
98.86
(80.00-156.50) |
|
CRP:
C-reactive protein; FEV1: Forced Expiratory Volume in the first second; GOLD:
The Global Initiative for Chronic Obstructive Lung Disease;
IQR:
Inter quartile range; mMRC: The Modified Medical Research Council Dyspnea
Scale; NLR: neutrophil- to lymphocyte ratio; PLR: platalet to lymphocyte ratio